A Non-Interventional Study of the Occurrence Rate of Non-Small Cell Lung Cancer, Colon Cancer, Breast Cancer, Gastric Cancer and Malignant Melanoma in Turkey, and Diagnosis and Treatment Characteristics
Occurrence Rate of Non-Small Cell Lung, Colon Cancer, Breast Cancer, Gastric Cancer and Malignant Melanoma in Turkey & Diagnosis and Treatment Characteristics Turkish "Non-Small Cell Lung-Colon-Gastric-Breast (CGB) Cancer and Malignant Melanoma" Study
1 other identifier
observational
32,277
1 country
31
Brief Summary
This non-interventional study will assess the occurrence rate of non-small cell lung cancer, colon cancer, breast cancer, gastric cancer and malignant melanoma in Turkey, and the diagnostic methods and treatments used. Data will be collected over 36 months.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Oct 2012
Typical duration for all trials
31 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 2012
CompletedFirst Submitted
Initial submission to the registry
January 18, 2013
CompletedFirst Posted
Study publicly available on registry
January 25, 2013
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
October 1, 2015
CompletedNovember 2, 2016
November 1, 2016
3 years
January 18, 2013
November 1, 2016
Conditions
Outcome Measures
Primary Outcomes (5)
Number of Participants with Malignant Melanoma (Occurrence Rate), Defined as New Cases Recorded in the Relevant Region in 1 Year/Population of the Region
36 months
Number of Participants with Non-Small Cell Lung Cancer (Occurrence Rate), Defined as New Cases Recorded in the Region in 1 Year Divided by (/) Population of the Region
36 months
Number of Participants with Colon Cancer (Occurrence Rate), Defined as New Cases Recorded in the Relevant Region in 1 Year/Population of the Region
36 months
Number of Participants with Breast Cancer (Occurrence Rate), Defined as New Cases Recorded in the Relevant Region in 1 Year/Population of the Region
36 months
Number of Participants with Gastric Cancer (Occurrence Rate), Defined as New Cases Recorded in the Relevant Region in 1 Year/Population of the Region
36 months
Secondary Outcomes (13)
Percentage of Participants Categorized by Tumor Size
36 months
Percentage of Participants Categorized by Histopathology Diagnosis
36 months
Percentage of Participants Categorized by the Staging System
36 months
Percentage of Participants Categorized by Surgery Type
36 months
Percentage of Participants Categorized by Type of Treatments Administered (ie, Adjuvant and Neoadjuvant Treatments)
36 months
- +8 more secondary outcomes
Study Arms (1)
Participants With Cancer
Participants from Turkey with non-small cell lung, colon cancer, breast cancer, gastric cancer and malignant melanoma will be included.
Eligibility Criteria
Participants with non-small cell lung cancer, colon cancer, breast cancer, gastric cancer and malignant melanoma in Turkey
You may qualify if:
- Participants diagnosed with non-small cell lung, colon, breast, gastric cancer and melanoma
- Participants who give consent to the collection of their information after the first record and pathological confirmation of their cancer
You may not qualify if:
- Participants not living in the city or representative region of the study center
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (31)
Unknown Facility
Adana, 01220, Turkey (Türkiye)
Unknown Facility
Adana, 01330, Turkey (Türkiye)
Unknown Facility
Afyonkarahisar, 03200, Turkey (Türkiye)
Unknown Facility
Ankara, 06100, Turkey (Türkiye)
Unknown Facility
Ankara, 06200, Turkey (Türkiye)
Unknown Facility
Ankara, 06280, Turkey (Türkiye)
Unknown Facility
Ankara, 06500, Turkey (Türkiye)
Unknown Facility
Ankara, 06800, Turkey (Türkiye)
Unknown Facility
Baıkesir, 10000, Turkey (Türkiye)
Unknown Facility
Bursa, 16040, Turkey (Türkiye)
Unknown Facility
Bursa, 16059, Turkey (Türkiye)
Unknown Facility
Denizli, 20070, Turkey (Türkiye)
Unknown Facility
Diyarbakır, 21280, Turkey (Türkiye)
Unknown Facility
Edirne, 22770, Turkey (Türkiye)
Unknown Facility
Erzurum, 25050, Turkey (Türkiye)
Unknown Facility
Gaziantep, 27100, Turkey (Türkiye)
Unknown Facility
Isparta, 32260, Turkey (Türkiye)
Unknown Facility
Istanbul, 34000, Turkey (Türkiye)
Unknown Facility
Istanbul, 34020, Turkey (Türkiye)
Unknown Facility
Istanbul, 34093, Turkey (Türkiye)
Unknown Facility
Istanbul, 34300, Turkey (Türkiye)
Unknown Facility
Istanbul, 34890, Turkey (Türkiye)
Unknown Facility
Izmir, 35100, Turkey (Türkiye)
Unknown Facility
Izmir, 35110, Turkey (Türkiye)
Unknown Facility
Izmir, 35340, Turkey (Türkiye)
Unknown Facility
Kayseri, 38039, Turkey (Türkiye)
Unknown Facility
Konya, 42080, Turkey (Türkiye)
Unknown Facility
Malatya, 44280, Turkey (Türkiye)
Unknown Facility
Sıhhiye, Ankara, 06100, Turkey (Türkiye)
Unknown Facility
Tokat Province, 60250, Turkey (Türkiye)
Unknown Facility
Trabzon, 61080, Turkey (Türkiye)
MeSH Terms
Conditions
Study Officials
- STUDY DIRECTOR
Clinical Trials
Hoffmann-La Roche
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 18, 2013
First Posted
January 25, 2013
Study Start
October 1, 2012
Primary Completion
October 1, 2015
Study Completion
October 1, 2015
Last Updated
November 2, 2016
Record last verified: 2016-11